Literature DB >> 14763202

10-year follow-up of women who elected quinacrine sterilization (QS) in Wonosobo, Central Java, Indonesia.

A Suhadi1, M Anwar, A Soejoenoes.   

Abstract

OBJECTIVES: To evaluate the safety and efficacy of quinacrine sterilization (QS) in Indonesia.
METHODS: During the period, August 1992 to October 1993, 200 women who had requested surgical sterilization volunteered for QS at the Wonosobo Regency Hospital, Central Java Province, Indonesia. The protocol called for transcervical insertion of 252 mg of quinacrine in the form of 7 cylindrical pellets and 55.5 mg of ibuprofen with a CuT-IUD (Kimia Farma) inserter during the proliferative phase of the menstrual cycle. A second procedure was done 4 weeks later. The technique used is essentially the same as inserting a CuT-IUD. Follow-up was scheduled at 6, 12, 24 and 48 months after the last insertion. In March 2003 additional monitoring was completed.
RESULTS: The 10-year cumulative pregnancy rate was 4.3 per 100 women with a follow-up rate of 93%. No pregnancies had occurred among these women since the 4-year follow-up. No long-term side effects or complications were reported.
CONCLUSIONS: After 10 years of use, QS was found to be safe and reasonably effective.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14763202     DOI: 10.1016/S0020-7292(03)90106-8

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  3 in total

1.  Hysteroscopic sterilization: history and current methods.

Authors:  James A Greenberg
Journal:  Rev Obstet Gynecol       Date:  2008

Review 2.  Techniques for the interruption of tubal patency for female sterilisation.

Authors:  Theresa A Lawrie; Regina Kulier; Juan Manuel Nardin
Journal:  Cochrane Database Syst Rev       Date:  2016-08-05

3.  Endometrial abnormalities on transvaginal ultrasonography and histopathology in women after quinacrine sterilization.

Authors:  Saira Afzal; Mulazim Hussain Bukhari
Journal:  Pak J Med Sci       Date:  2014-07       Impact factor: 1.088

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.